anti-IgE monoclonal antibody (Harbin Pharmaceutical Group Bioengineering)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-IgE monoclonal antibody (Harbin Pharmaceutical Group Bioengineering)
Drug Alias Nameanti-IgE MAb (Harbin Pharmaceutical Group Bioengineering)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionImmunoglobulin E inhibitors
TargetsImmunoglobulin E
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesHarbin Pharmaceutical Group Biological Engineering Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHarbin Pharmaceutical Group Biological Engineering Co Ltd
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A